Projects

Mgr. Božena Smolková, PhD.
senior scientist

International

Current
  • Reversing Epitranscriptomic Alterations for CHemosensitization of Pancreatic Cancer
    Program: ERANET
    Duration: 1. 9. 2024 – 31. 8. 2027
  • Modelling immunotherapy response and toxicity in cancer
    Program: COST
    Duration: 2. 11. 2022 – 1. 11. 2026
  • Identification of biological markers for prevention and translational medicine in pancreatic cancer
    Program: COST
    Duration: 11. 10. 2022 – 10. 10. 2026
Finished
  • Resistance under treatment in breast cancer
    Program: ERANET
    Duration: 1. 8. 2020 – 31. 5. 2024
  • A4L_ACTIONS Deciphering interindividual differences in extracellular vesicle-mediated gene therapy response
    Program: Other
    Duration: 1. 11. 2022 – 31. 10. 2023
  • Strategies to strengthen scientific excellence and innovation capacity for early diagnosis of gastrointestinal cancer
    Program: Horizon 2020
    Duration: 1. 10. 2019 – 30. 6. 2023
  • Establishing an algorithm for the early diagnosis and follow-up of patients with pancreatic neuroendocrine tumors
    Program: ERANET
    Duration: 1. 9. 2019 – 31. 3. 2023
  • Epigenotoxicity of nanomaterials
    Program: Inter-academic agreement
    Duration: 1. 1. 2020 – 31. 12. 2022
  • Targeted combination therapy of colon cancer with therapeutic gene/drug loaded novel dendritic nanocarriers
    Program: Bilateral - other
    Duration: 3. 9. 2018 – 30. 11. 2022
  • INNOVATIVE PARTNERSHIP FOR ACTION AGAINST CANCER
    Program: Other
    Duration: 1. 4. 2018 – 31. 12. 2021
  • Innovative Nanopharmaceuticals: Targeting Breast Cancer Stem Cells by a Novel Combination of Epigenetic and Anticancer Drugs with Gene Therapy
    Program: ERANET
    Duration: 1. 1. 2017 – 30. 6. 2021
  • High level Integrated Sensor for Nano Toxicity Screening
    Program: Horizon 2020
    Duration: 1. 4. 2016 – 31. 3. 2019

National

Current
  • Targeting high-order chromatin regulation for the treatment of poor prognosis uveal melanoma
    Program: SRDA
    Duration: 1. 7. 2024 – 30. 6. 2028
  • DNA methylation biomarkers as a tool for the implementation of liquid biopsy in uveal melanoma
    Program: VEGA
    Duration: 1. 1. 2024 – 31. 12. 2027
  • Innovative approaches to the diagnosis and treatment of pancreatic ductal adenocarcinoma
    Program:
    Duration: 1. 9. 2024 – 30. 6. 2026
  • Reprogramming pancreatic ductal adenocarcinoma microenvironment towards immunotherapy
    Program: SRDA
    Duration: 1. 7. 2022 – 30. 6. 2026
Finished
  • Suicide gene therapy mediated by mesenchymal stromal and pancreatic tumor cell-excreted extracellular vesicles in the treatment of pancreatic ductal adenocarcinoma
    Program: SRDA
    Duration: 1. 7. 2021 – 30. 6. 2025
  • Exosomes secreted by cancer cells of digestive organs, their characterization and modification by the CRISPR/Cas9 system for the aim of use in therapy
    Program: VEGA
    Duration: 1. 1. 2021 – 31. 12. 2024
  • Development of patients derived xenografts models and their utilization for personalized treatment of uveal melanoma
    Program: VEGA
    Duration: 1. 1. 2021 – 31. 12. 2024
  • Markers overlapping chemoresistance and metastatic potential in colorectal cancer - aldehyde dehydrogenase and its clinical relevance
    Program: Other projects
    Duration: 1. 11. 2019 – 31. 12. 2022
  • TArgetiNg Dna mEthylation by epigenetic editing and its implementation into personalised diagnostics and therapy of uveal Melanoma
    Program: SRDA
    Duration: 1. 8. 2018 – 31. 12. 2022
  • The dynamics of inflammation-induced epigenetic changes during epithelial-to-mesenchymal transition and their role in human pancreatic ductal adenocarcinoma progression
    Program: VEGA
    Duration: 1. 1. 2018 – 31. 12. 2021
  • Cellular and molecular traits of human metastasis-initiating cells at different stages of metastasis development.
    Program: VEGA
    Duration: 1. 1. 2017 – 31. 12. 2020
  • DNA methylation profiles in genes associated with breast cancer metasasising
    Program: VEGA
    Duration: 1. 1. 2015 – 31. 12. 2018
  • Histone modification and DNA methylation relationship in transcription silencing of cancer associated genes
    Program: VEGA
    Duration: 1. 1. 2013 – 31. 12. 2016
  • Implementation of methods for analysis of epigenetic changes in genes involved in epithelial-mesenchymal transition in breast cancer
    Program: VEGA
    Duration: 1. 1. 2014 – 31. 12. 2016
  • Identification of predictive epigenetic biomarkers in breast cancers
    Program: SRDA
    Duration: 1. 5. 2011 – 31. 8. 2014
Employees